ACQUISITION OF GROUP A MEDICINES FOR THE EL BATAN DAY HOSPITAL OUTPATIENT CLINICAL SURGICAL CENTER

This tender concerns the procurement of Group A medicines for the El Batan Day Hospital Outpatient Clinical Surgical Center. The specific item required is Gliclazide, an oral solid medication in prolonged-release formulation, with a dosage of 60 mg, supplied in blister/strip boxes. The required quantity is 56,980 units, with an estimated value of USD 27,066.00. The contracting entity is the CENTRO CLINICO QUIRURGICO AMBULATORIO HOSPITAL DEL DIA EL BATAN. The procurement method to be employed is Electronic Reverse Auction (Subasta Inversa Electrónica). This process aims to secure essential pharmaceutical supplies for the El Batan Day Hospital, ensuring the continuity of medical services provided to patients. Interested suppliers are invited to participate in the electronic reverse auction, where they will compete to offer the most competitive pricing for the specified medication. The tender process is managed under code SIE-CCQAHDELBATAN-2025-0006-2808. The focus on Group A medicines indicates a priority for essential drugs within the hospital's formulary. The selection of an electronic reverse auction suggests a strategy to achieve cost efficiencies while maintaining the quality and availability of critical pharmaceutical products for the center's operations.

This is a supplies contract in the governance and public administration sector. Located in Ecuador, Latin America, this opportunity is open to firms and consortiums, with an estimated budget of USD 27,066.

Published through SERCOP Ecuador, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the governance and public administration sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.